Literature DB >> 1616911

Transport of HDL cholesterol esters to the liver is not diminished by probucol treatment in rats.

B M Richard1, M A Pfeuffer, R C Pittman.   

Abstract

This study examined the relation of decreased high density lipoprotein (HDL) levels in probucol-fed rats and the transport of HDL cholesterol esters (CEs) to the liver. HDLs from both control rats and rats fed 1% probucol for 3 weeks were doubly labeled in their CE and apolipoprotein A-I moieties with intracellularly trapped tracers and then intravenously injected into probucol-fed or control rats for determination of plasma decay kinetics and sites of tracer uptake. Results for HDL from control and probucol-fed rats were not different. The fractional catabolic rate (FCR) of plasma HDL CE was significantly increased by probucol feeding (23%) so that mass transport of HDL CE through the plasma compartment was not significantly different from that in control rats. The plasma FCR for apolipoprotein A-I did not change. Similarly, the FCR for uptake of HDL CE by the liver increased on probucol feeding (20%), resulting in a near-normal rate of HDL CE mass uptake, whereas the FCR for HDL particle uptake (measured by apolipoprotein A-I uptake) did not change. Thus, the maintenance of near-normal HDL CE uptake by the liver was exclusively due to increased selective uptake (32%). To the extent that hepatic uptake of HDL CE mediates reverse cholesterol transport, that process was not significantly compromised in rats fed 1% probucol.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1616911     DOI: 10.1161/01.atv.12.7.862

Source DB:  PubMed          Journal:  Arterioscler Thromb        ISSN: 1049-8834


  1 in total

1.  Targeted mutation reveals a central role for SR-BI in hepatic selective uptake of high density lipoprotein cholesterol.

Authors:  M L Varban; F Rinninger; N Wang; V Fairchild-Huntress; J H Dunmore; Q Fang; M L Gosselin; K L Dixon; J D Deeds; S L Acton; A R Tall; D Huszar
Journal:  Proc Natl Acad Sci U S A       Date:  1998-04-14       Impact factor: 11.205

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.